OKYO Pharma Aktie
WKN DE: A3DLA6 / ISIN: US6793451088
08.01.2024 13:59:45
|
OKYO Pharma Says Phase 2 Study Of OK-101 Did Not Meet Primary Goal
(RTTNews) - OKYO Pharma Limited (OKYO) Monday said Phase 2 study of OK-101 ophthalmic solution in patients with dry eye disease did not meet its primary goal.
However, a statistically significant improvement was observed in both a sign endpoint of total conjunctival staining and two symptoms endpoints of dry eye disease, burning/stinging and blurred vision, the company said in a statement.
According to OKYO Pharma, this first-in-human trial of OK-101 established a clear and informed path for further development in Phase 3 registration trials.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu OKYO Pharma Limited (spons. ADRs)mehr Nachrichten
Keine Nachrichten verfügbar. |